Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | NMUR2 | Q9GZQ4 | 7/20 | 0.59 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.59 |
| ▸ | TACR1 | P25103 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360576 | 0.92 | F2 (0.59) | OPRD1OPRM1OPRK1F2NMUR2 | |
| SCHEMBL29474228 | 0.92 | F2 (0.59) | OPRD1OPRM1OPRK1F2NMUR2 | |
| Substance P SCHEMBL1116347 | 0.86 | OPRD1 (0.67) | OPRD1OPRM1OPRK1F2NMUR2 | |
| Substance P SCHEMBL29831869 | 0.86 | OPRD1 (0.67) | OPRD1OPRM1OPRK1F2NMUR2 | |
| Substance P SCHEMBL19057679 | 0.86 | OPRD1 (0.67) | OPRD1OPRM1OPRK1F2NMUR2 | |
| SCHEMBL29498256 | 0.86 | OPRD1 (0.67) | OPRD1OPRM1OPRK1F2NMUR2 | |
| Substance P SCHEMBL17887651 | 0.86 | OPRD1 (0.67) | OPRD1OPRM1OPRK1F2NMUR2 | |
| Substance P SCHEMBL18769078 | 0.86 | OPRD1 (0.67) | OPRD1OPRM1OPRK1F2NMUR2 | |
| SCHEMBL29698606 | 0.86 | NMUR2 (0.71) | OPRD1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL3539226 | 0.86 | NMUR2 (0.71) | OPRD1OPRM1OPRK1NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739655-A2 | SUBSTITUTED 2-PHENYLPIPERIDINE COMPOUNDS FOR USE IN THE DIAGNOSIS, TREATMENT AND/OR PREVENTION OF CANCER | Nestor, Marika (SE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008409-A2 | SUBSTITUTED 2-PHENYLPIPERIDINE COMPOUNDS FOR USE IN THE DIAGNOSIS, TREATMENT AND/OR PREVENTION OF CANCER | JHA PREETI (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-3509574-B1 | MEDICINAL USE OF SERRULATANE DITERPENES | KYNAN DUKE IP LLC (US) | 2024-11-27 | — | — | EP | disclosed |
| EP-4431512-A1 | NOVEL DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS | Bayer Consumer Care AG (CH) | 2024-09-18 | — | — | EP | disclosed |
| EP-3337486-B1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS INC (US) | 2024-04-03 | — | — | EP | disclosed |
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4046995-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11414377-B2 | Modulator of metabotropic and ionotropic transmembrane receptors and use thereof | IBD THERAPEUTICS LLC (RU) | 2022-08-16 | — | — | US | disclosed |
| EP-3256466-B9 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-3256466-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414377-B2 | Modulator of metabotropic and ionotropic transmembrane receptors and use thereof | TRPM8, TRPV1, TRPA1 | OPRD1 53/4885OPRM1 31/4885OPRK1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.